Dopa-responsive dystonia

Dopa-responsive dystonia (DRD) is a movement disorder historically recognized for its dramatic response to low doses of L-dopa. While the classic presentation involves childhood-onset dystonia with diurnal fluctuations and mild parkinsonism, the clinical and genetic landscape has become increasingly complex. This paper seeks to resolve diagnostic confusion by clearly defining the clinical syndrome and differentiating it from other disorders that share similar symptoms.

The authors define DRD as a selective nigrostriatal dopamine deficiency caused by genetic defects in the dopamine synthetic pathway, specifically without the nigral cell loss seen in Parkinson's disease. Because this is a biochemical disorder rather than a neurodegenerative one, patients should theoretically experience complete symptom resolution with L-dopa therapy.

To address the heterogeneity of atypical cases, the authors propose the term "DRD-plus." This category encompasses inherited disorders of dopamine metabolism that present with DRD-like features alongside additional, more severe symptoms such as psychomotor retardation, convulsions, or systemic dysfunction. This distinction is crucial for clinicians, as DRD-plus cases may not be fully reversible with standard L-dopa treatment and may require broader therapeutic strategies, such as BH4 or serotonin supplementation.

Distinguishing DRD from juvenile Parkinson's disease (JPD) is a significant clinical challenge. While both may show early L-dopa responsiveness, JPD is a neurodegenerative condition that eventually leads to motor fluctuations and dyskinesias. The authors emphasize that imaging studies, such as dopamine transporter (DAT) imaging or fluorodopa PET, are essential for differentiation, as these will show normal results in DRD but abnormal uptake in JPD.

Genetic testing for GCH-1 mutations is a primary diagnostic tool, but it is not infallible. The authors caution that genetic studies can yield false negatives, and the presence of a mutation does not always guarantee a specific clinical phenotype. Clinicians must rely on a combination of biochemical analysis (e.g., CSF neopterin levels), clinical evaluation, and longitudinal follow-up to ensure that an identified genetic defect is the true cause of the patient's symptoms rather than a coincidental finding.